208 related articles for article (PubMed ID: 29969155)
1. Clinical significance of PDEF factor expression and its relation to androgen receptor in ER
Cao L; Li C; Xu C; Xiang G; Liu F; Liu X; Jiao J; Lv S; Niu Y
Histopathology; 2018 Nov; 73(5):819-831. PubMed ID: 29969155
[TBL] [Abstract][Full Text] [Related]
2. AR-PDEF pathway promotes tumour proliferation and upregulates MYC-mediated gene transcription by promoting MAD1 degradation in ER-negative breast cancer.
Cao L; Xu C; Xiang G; Liu F; Liu X; Li C; Liu J; Meng Q; Jiao J; Niu Y
Mol Cancer; 2018 Sep; 17(1):136. PubMed ID: 30217192
[TBL] [Abstract][Full Text] [Related]
3. A high AR:ERα or PDEF:ERα ratio predicts a sub-optimal response to tamoxifen therapy in ERα-positive breast cancer.
Cao L; Xiang G; Liu F; Xu C; Liu J; Meng Q; Lyu S; Wang S; Niu Y
Cancer Chemother Pharmacol; 2019 Sep; 84(3):609-620. PubMed ID: 31297554
[TBL] [Abstract][Full Text] [Related]
4. Prostate-derived Ets transcription factor overexpression is associated with nodal metastasis and hormone receptor positivity in invasive breast cancer.
Turcotte S; Forget MA; Beauseigle D; Nassif E; Lapointe R
Neoplasia; 2007 Oct; 9(10):788-96. PubMed ID: 17971898
[TBL] [Abstract][Full Text] [Related]
5. Prostate-derived Ets factor, an oncogenic driver in breast cancer.
Sood AK; Geradts J; Young J
Tumour Biol; 2017 May; 39(5):1010428317691688. PubMed ID: 28468594
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
Aleskandarany MA; Abduljabbar R; Ashankyty I; Elmouna A; Jerjees D; Ali S; Buluwela L; Diez-Rodriguez M; Caldas C; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Sep; 159(2):215-27. PubMed ID: 27514395
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of Amphiregulin and the correlation with androgen receptor in invasive breast cancer.
Xiang G; Liu F; Liu J; Meng Q; Li N; Niu Y
Pathol Res Pract; 2019 Jun; 215(6):152414. PubMed ID: 31040043
[TBL] [Abstract][Full Text] [Related]
8. FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients.
Rangel N; Fortunati N; Osella-Abate S; Annaratone L; Isella C; Catalano MG; Rinella L; Metovic J; Boldorini R; Balmativola D; Ferrando P; Marano F; Cassoni P; Sapino A; Castellano I
BMC Cancer; 2018 Jul; 18(1):703. PubMed ID: 29970021
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of prostate-derived Ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells.
Tsui KH; Chung LC; Feng TH; Chang PL; Juang HH
Int J Cancer; 2012 Jun; 130(12):2812-23. PubMed ID: 21780100
[TBL] [Abstract][Full Text] [Related]
10. The immunohistochemical expression and potential prognostic value of HDAC6 and AR in invasive breast cancer.
Li C; Cao L; Xu C; Liu F; Xiang G; Liu X; Jiao J; Niu Y
Hum Pathol; 2018 May; 75():16-25. PubMed ID: 29180246
[TBL] [Abstract][Full Text] [Related]
11. The expression and prognostic role of EBP1 and relationship with AR in HER2+ breast cancer.
Liu J; Xu C; Xu D; Cao L; Xue H; Meng Q; Niu Y
Virchows Arch; 2020 Aug; 477(2):279-289. PubMed ID: 32086588
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers.
Tsang JY; Ni YB; Chan SK; Shao MM; Law BK; Tan PH; Tse GM
Ann Surg Oncol; 2014 Jul; 21(7):2218-28. PubMed ID: 24639191
[TBL] [Abstract][Full Text] [Related]
13. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
[TBL] [Abstract][Full Text] [Related]
14. Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression.
Sood AK; Saxena R; Groth J; Desouki MM; Cheewakriangkrai C; Rodabaugh KJ; Kasyapa CS; Geradts J
Hum Pathol; 2007 Nov; 38(11):1628-38. PubMed ID: 17521701
[TBL] [Abstract][Full Text] [Related]
15. Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort.
Elebro K; Borgquist S; Simonsson M; Markkula A; Jirström K; Ingvar C; Rose C; Jernström H
Clin Cancer Res; 2015 Aug; 21(16):3640-50. PubMed ID: 25904752
[TBL] [Abstract][Full Text] [Related]
16. Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival.
Okano M; Oshi M; Butash AL; Asaoka M; Katsuta E; Peng X; Qi Q; Yan L; Takabe K
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151151
[TBL] [Abstract][Full Text] [Related]
17. Lin28A and androgen receptor expression in ER-/Her2+ breast cancer.
Shen H; Yang Y; Zhao L; Yuan J; Niu Y
Breast Cancer Res Treat; 2016 Feb; 156(1):135-47. PubMed ID: 26944953
[TBL] [Abstract][Full Text] [Related]
18. PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells.
Buchwalter G; Hickey MM; Cromer A; Selfors LM; Gunawardane RN; Frishman J; Jeselsohn R; Lim E; Chi D; Fu X; Schiff R; Brown M; Brugge JS
Cancer Cell; 2013 Jun; 23(6):753-67. PubMed ID: 23764000
[TBL] [Abstract][Full Text] [Related]
19. The role of the AR/ER ratio in ER-positive breast cancer patients.
Rangel N; Rondon-Lagos M; Annaratone L; Osella-Abate S; Metovic J; Mano MP; Bertero L; Cassoni P; Sapino A; Castellano I
Endocr Relat Cancer; 2018 Mar; 25(3):163-172. PubMed ID: 29386247
[TBL] [Abstract][Full Text] [Related]
20. Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer.
Ghadersohi A; Sharma S; Zhang S; Azrak RG; Wilding GE; Manjili MH; Li F
Prostate; 2011 Aug; 71(11):1178-88. PubMed ID: 21656828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
